针对三阴性乳腺癌的治疗方法:对抗FGFR的观点
Jinhao Chen1,2,3, Qianru Wang1,3, Hongyan Wu1,3
1Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, Hubei, China.
Frontiers in oncology
|March 26, 2025
概括
向纤维细胞生长因子/纤维细胞生长因子受体 (FGF/FGFR) 途径为对抗三阴性乳腺癌 (TNBC) 提供了一个有希望的策略. 抑制这一轴会破坏瘤的微环境,从而有可能克服治疗阻力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 由于瘤异质性和有限的治疗选择,三阴性乳腺癌 (TNBC) 的预后不佳.
- 瘤微环境 (TME) 显著影响TNBC的进展,促进增殖,血管生成,免疫抑制和耐药性.
- 纤维细胞生长因子/纤维细胞生长因子受体 (FGF/FGFR) 信号通路在TME形成和TNBC发育中起着至关重要的作用.
研究的目的:
- 评估抑制FGF/FGFR轴作为TNBC治疗策略的潜力.
- 探索FGF/FGFR信号在TNBC进展中的作用,包括TME调制,血管生成和免疫逃避.
- 通过了解FGF/FGFR通路的机制,确定TNBC治疗的新治疗点和策略.
主要方法:
- 本综述综合了关于TNBC中FGF/FGFR信号通路的当前研究.
- 分析FGF/FGFR过度激活对TME组件和TNBC特征的影响.
- 在TNBC模型中评估关于FGF/FGFR抑制剂的临床前和临床数据.
主要成果:
- 过度激活的FGFRs通过影响TME事件,有助于TNBC生长,迁移和耐药性.
- 抑制FGF/FGFR轴显示出破坏瘤血管生成和克服免疫逃避的潜力.
- 准FGF/FGFR信号可能会阻碍TNBC的扩散,并提高对现有疗法的敏感性.
结论:
- 抑制FGF/FGFR轴是TNBC的可行的治疗策略,解决TME的关键方面.
- 对FGF/FGFR通路抑制剂的进一步研究可能会导致TNBC的创新治疗方法.
- 了解FGF/FGFR机制为开发新型TNBC药物和治疗方法提供了基础.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Immunotherapy
450
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
450
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K


